These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 29055152)

  • 1. Predominance of regorafenib over sorafenib: Restoration of membrane-bound MICA in hepatocellular carcinoma cells.
    Arai J; Goto K; Stephanou A; Tanoue Y; Ito S; Muroyama R; Matsubara Y; Nakagawa R; Morimoto S; Kaise Y; Lim LA; Yoshida H; Kato N
    J Gastroenterol Hepatol; 2018 May; 33(5):1075-1081. PubMed ID: 29055152
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Leukotriene receptor antagonists enhance HCC treatment efficacy by inhibiting ADAMs and suppressing MICA shedding.
    Arai J; Goto K; Otoyama Y; Nakajima Y; Sugiura I; Kajiwara A; Tojo M; Ichikawa Y; Uozumi S; Shimozuma Y; Uchikoshi M; Sakaki M; Nozawa H; Nakagawa R; Muroyama R; Kato N; Yoshida H
    Cancer Immunol Immunother; 2021 Jan; 70(1):203-213. PubMed ID: 32683508
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Retinoids Decrease Soluble MICA Concentration by Inhibiting the Enzymatic Activity of ADAM9 and ADAM10.
    Otoyama Y; Arai J; Goto K; Nozawa H; Nakagawa R; Muroyama R; Sugiura I; Nakajima Y; Kajiwara A; Tojo M; Ichikawa Y; Uozumi S; Shimozuma Y; Uchikoshi M; Sakaki M; Kato N; Yoshida H
    Anticancer Res; 2021 May; 41(5):2307-2320. PubMed ID: 33952456
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Knockout of ADAM10 enhances sorafenib antitumor activity of hepatocellular carcinoma in vitro and in vivo.
    Zhang W; Liu S; Liu K; Ji B; Wang Y; Liu Y
    Oncol Rep; 2014 Nov; 32(5):1913-22. PubMed ID: 25176394
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sorafenib inhibits the shedding of major histocompatibility complex class I-related chain A on hepatocellular carcinoma cells by down-regulating a disintegrin and metalloproteinase 9.
    Kohga K; Takehara T; Tatsumi T; Ishida H; Miyagi T; Hosui A; Hayashi N
    Hepatology; 2010 Apr; 51(4):1264-73. PubMed ID: 20099300
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anticancer chemotherapy inhibits MHC class I-related chain a ectodomain shedding by downregulating ADAM10 expression in hepatocellular carcinoma.
    Kohga K; Takehara T; Tatsumi T; Miyagi T; Ishida H; Ohkawa K; Kanto T; Hiramatsu N; Hayashi N
    Cancer Res; 2009 Oct; 69(20):8050-7. PubMed ID: 19826051
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enzymatic inhibition of MICA sheddase ADAM17 by lomofungin in hepatocellular carcinoma cells.
    Arai J; Goto K; Tanoue Y; Ito S; Muroyama R; Matsubara Y; Nakagawa R; Kaise Y; Lim LA; Yoshida H; Kato N
    Int J Cancer; 2018 Nov; 143(10):2575-2583. PubMed ID: 29873070
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of CD133 confers malignant potential by regulating metalloproteinases in human hepatocellular carcinoma.
    Kohga K; Tatsumi T; Takehara T; Tsunematsu H; Shimizu S; Yamamoto M; Sasakawa A; Miyagi T; Hayashi N
    J Hepatol; 2010 Jun; 52(6):872-9. PubMed ID: 20395004
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Shedding of endogenous MHC class I-related chain molecules A and B from different human tumor entities: heterogeneous involvement of the "a disintegrin and metalloproteases" 10 and 17.
    Chitadze G; Lettau M; Bhat J; Wesch D; Steinle A; Fürst D; Mytilineos J; Kalthoff H; Janssen O; Oberg HH; Kabelitz D
    Int J Cancer; 2013 Oct; 133(7):1557-66. PubMed ID: 23526433
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hypoxia-induced shedding of MICA and HIF1A-mediated immune escape of pancreatic cancer cells from NK cells: role of circ_0000977/miR-153 axis.
    Ou ZL; Luo Z; Wei W; Liang S; Gao TL; Lu YB
    RNA Biol; 2019 Nov; 16(11):1592-1603. PubMed ID: 31402756
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ADAM10 is overexpressed in human hepatocellular carcinoma and contributes to the proliferation, invasion and migration of HepG2 cells.
    Yuan S; Lei S; Wu S
    Oncol Rep; 2013 Oct; 30(4):1715-22. PubMed ID: 23912592
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Successful Identification of a Novel Therapeutic Compound for Hepatocellular Carcinoma Through Screening of ADAM9 Inhibitors.
    Ogawa K; Chiba T; Nakamura M; Arai J; Zhang J; Ma Y; Qiang NA; Ao J; Yumita S; Ishino T; Kan M; Iwanaga T; Nakagawa M; Fujiwara K; Sakuma T; Kanzaki H; Koroki K; Kusakabe Y; Kobayashi K; Kanogawa N; Kiyono S; Kondo T; Nakagawa R; Ogasawara S; Muroyama R; Nakamoto S; Kanda T; Maruyama H; Kato J; Matsumoto S; Arai T; Motohashi S; Kato N
    Anticancer Res; 2023 Mar; 43(3):1043-1052. PubMed ID: 36854524
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A disintegrin and metalloprotease (ADAM)10 is highly expressed in hepatocellular carcinoma and is associated with tumour progression.
    Zhang W; Liu S; Liu K; Wang Y; Ji B; Zhang X; Liu Y
    J Int Med Res; 2014 Jun; 42(3):611-8. PubMed ID: 24670536
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Silencing ADAM10 inhibits the in vitro and in vivo growth of hepatocellular carcinoma cancer cells.
    Liu S; Zhang W; Liu K; Ji B; Wang G
    Mol Med Rep; 2015 Jan; 11(1):597-602. PubMed ID: 25323956
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interleukin-1β enhances the production of soluble MICA in human hepatocellular carcinoma.
    Kohga K; Tatsumi T; Tsunematsu H; Aono S; Shimizu S; Kodama T; Hikita H; Yamamoto M; Oze T; Aketa H; Hosui A; Miyagi T; Ishida H; Hiramatsu N; Kanto T; Hayashi N; Takehara T
    Cancer Immunol Immunother; 2012 Sep; 61(9):1425-32. PubMed ID: 22302133
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of human UDP-glucuronosyltransferase enzymes by lapatinib, pazopanib, regorafenib and sorafenib: Implications for hyperbilirubinemia.
    Miners JO; Chau N; Rowland A; Burns K; McKinnon RA; Mackenzie PI; Tucker GT; Knights KM; Kichenadasse G
    Biochem Pharmacol; 2017 Apr; 129():85-95. PubMed ID: 28065859
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regulation of ADAM10 and ADAM17 by Sorafenib Inhibits Epithelial-to-Mesenchymal Transition in Epstein-Barr Virus-Infected Retinal Pigment Epithelial Cells.
    Park GB; Kim D; Kim YS; Kim JW; Sun H; Roh KH; Yang JW; Hur DY
    Invest Ophthalmol Vis Sci; 2015 Aug; 56(9):5162-73. PubMed ID: 26244291
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Restoration of miR-193b sensitizes Hepatitis B virus-associated hepatocellular carcinoma to sorafenib.
    Mao K; Zhang J; He C; Xu K; Liu J; Sun J; Wu G; Tan C; Zeng Y; Wang J; Xiao Z
    Cancer Lett; 2014 Oct; 352(2):245-52. PubMed ID: 25034398
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synergistic effects of co-expression plasmid‑based ADAM10-specific siRNA and GRIM-19 on hepatocellular carcinoma in vitro and in vivo.
    Liu S; Zhang W; Liu K; Wang Y; Ji B; Liu Y
    Oncol Rep; 2014 Dec; 32(6):2501-10. PubMed ID: 25242535
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ADAM10 overexpression confers resistance to doxorubicin-induced apoptosis in hepatocellular carcinoma.
    Yang CL; Jiang FQ; Xu F; Jiang GX
    Tumour Biol; 2012 Oct; 33(5):1535-41. PubMed ID: 22581584
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.